Hepatitis in China - Liver Let Die?

Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued transmission from mother to child (for HBV) and transmission via blood transfusions (HCV) means that HBV and HCV are likely to remain a problem.

Scope of this title:
- Analysis of the current dynamics of the Chinese hepatitis market through primary research data from 176 physicians, supported by key opinion leaders
- Identification of drivers and resistors of the Chinese hepatitis market, and how the Chinese healthcare system impacts these market-shaping factors
- Examination of key hepatitis drug regimens for hepatitis in China, and factors affecting prescription trends underlying these regimens
- Assessment of the differences between China and the 7 major markets in terms of HBV and HCV transmission and diagnosis

Highlights of this title:
Our physician research indicated that HBV incidence is decreasing in China. In contrast to the seven major markets, where most patients acquire HBV sexually, perinatal transmission is the dominant HBV transmission route, which impacts on HBV disease progression and effectiveness of drug therapy.

Chinese physicians believe that HCV incidence may be increasing in China. Blood transfusion is though to be the dominant HCV transmission route in China, while in the seven major markets, HCV is mainly acquired through intravenous drug use.

Chinese physicians do not consider any HBV therapy a gold-standard, although lamivudine is the most prescribed first-line therapy, while adefovir is the most prescribed second-line therapy. While treatment choice is more limited for HCV, the Chinese HCV market is highly fragmented, with treatment differing significantly between regions.

Reasons to order your copy:
- Review the clinical and commercial factors shaping the uptake of hepatitis products in China, and the opportunities and threats facing the market
- Gain insight into HBV and HCV prevalence, transmission and coinfection in China
- Evaluate unmet needs in Chinas hepatitis market and capitalize on these opportunities to develop commercial strategies to increase market penetration